Status:
TERMINATED
Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Lead Sponsor:
Wayne State University
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
20-59 years
Brief Summary
* The investigators are conducting a magnetic resonance imaging (MRI) study comparing two MRI contrast agents in people with clinically isolated syndrome and relapsing remitting multiple sclerosis (MS...
Detailed Description
Rationale/Goal: The use of contrast agents in magnetic resonance imaging (MRI) has been a gold standard in diagnosing multiple sclerosis (MS). One active lesion (i.e. enhanced after the injection of c...
Eligibility Criteria
Inclusion
- MS Patients:
- Patients who suffer from clinically definite MS with a RR phenotype or CIS
- Age range from 20-59 years old
- Not pregnant or nursing
- Able to understand and sign a consent form
- No contraindication to MRI and contrast agent
- Controls:
- Control is a healthy volunteer
- Aged from 20-59 years old
- Not pregnant or nursing
- Able to understand and sign a consent form
- No contraindication to MRI and contrast agent
Exclusion
- MS Patients:
- History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder other than MS or substances abuse
- Currently receiving chemo therapy, on dialysis
- Known contraindication to MRI such as pacemaker, pregnancy, other non-MR compatible implanted device
- Allergic to MRI contrast Patients with moderate to severe kidney disease that have impaired ability to filter the contrast agents (serum creatinine \> 1.8 mg/dL).
- Younger than 20 or older than 59
- Pregnancy or nursing
- Unable to understand and sign a consent form
- Controls:
- History of other major illness such as diabetes, chronic renal disease, a prior known neurological disorder or substances abuse
- Currently receiving chemo therapy, on dialysis
- Known contraindication to MRI such as pacemaker, pregnancy, other non-MR compatible implanted device
- Allergic to MRI contrast Controls with moderate to severe kidney disease that have impaired ability to filter the contrast agents (serum creatinine \> 1.8 mg/dL).
- Younger than 20 or older than 59
- Pregnancy or nursing
- Unable to understand and sign a consent form
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01836055
Start Date
January 1 2012
End Date
February 1 2014
Last Update
December 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wayne State University
Detroit, Michigan, United States, 48201